Skip to content

Cencora医药

US · COR #374 按市值排名 上市于 1970
340.92 -0.49 -0.14%
实时 - 追踪5344个代码 - 心跳于466秒前 · 2026-10-16 19:30

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了6家。
  • 机构持股总比例下降了0.2个百分点。

机构持股

机构持股比例
102.58% -0.15pp
机构数量
1,600 -6
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund83.30%
Private Company6.79%
Public Company4.14%
Hedge Fund3.68%
Government Pension Fund2.45%
Sovereign Wealth Fund1.32%
Insurance Company0.39%
Individual/Insider0.38%
Family Office/Trust0.24%

主要股东 截至 2026-06-30

BlackRock 9.54% · 18.21M 股
T. Rowe Price Group, Inc. 7.62% · 14.54M 股
Vanguard Capital Management, LLC 7.07% · 13.49M 股
Walgreens Boots Alliance Holdings LLC 5.04% · 9.62M 股
Vanguard Portfolio Management, LLC 5.04% · 9.61M 股
Other 65.69%
State Street Global Advisors 4.86% · 9.27M 股
Geode Capital Management, LLC 2.86% · 5.45M 股
J.P. Morgan Asset Management, Inc. 2.79% · 5.32M 股
Boston Partners Global Investors, Inc. 2.55% · 4.87M 股
Wellington Management Group 2.39% · 4.56M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 30次买入 · 18次卖出

姓名职务持股比例
Steven Collis Chairperson & CEO 0.20%
James Cleary Chief Financial Officer 0.08%
Robert Mauch Chief Operating Officer 0.03%
Mark M. Durcan Lead Independent Director 0.02%
Silvana Battaglia Executive Vice President 0.01%
Elizabeth Campbell Chief Legal Officer 0.01%
Lon Greenberg Independent Director 0.01%
Lazarus Krikorian Chief Accounting Officer 0.01%
Dennis Nally Independent Director 0.01%
Pawan Verma Executive VP, Chief Data & Information Officer 0.00%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-30 Robert Sanchez Independent Director Other Acquisition +275 --
2026-09-30 Robert Sanchez Independent Director Initial Statement of Beneficial 0 --
2026-09-30 Lazarus Krikorian Chief Accounting Officer Open Market Disposition -986 $303.18
2026-09-15 Lon Greenberg Independent Director Open Market Disposition -1,280 $321.30
2026-09-10 Silvana Battaglia Executive Vice President Intent to Sell (Form 144) -1,324 $325.00
2026-09-03 James Cleary Chief Financial Officer Intent to Sell (Form 144) -10,000 $335.17
2026-08-31 Silvana Battaglia Executive Vice President Intent to Sell (Form 144) -6,593 $330.00
2026-08-31 Lazarus Krikorian Chief Accounting Officer Automatic Disposition -985 $325.97
2026-08-23 Elizabeth Campbell Chief Legal Officer Open Market Disposition -11,300 $324.12
2026-08-05 James Cleary Chief Financial Officer Intent to Sell (Form 144) -20,000 $316.65
2026-07-30 Lauren Tyler Independent Director Other Acquisition +97 $311.34
2026-07-30 Dennis Nally Independent Director Other Acquisition +113 $311.34
2026-07-30 Ellen R. Cooper Independent Director Other Acquisition +97 $311.34
2026-06-29 Silvana Battaglia Executive Vice President Other Acquisition +58 $240.53
2026-06-29 Elizabeth Campbell Chief Legal Officer Other Acquisition +49 $240.53
2026-06-28 Eva Boratto Chief Financial Officer Other Derivative Acquisition +21,304 --
2026-06-28 Eva Boratto Chief Financial Officer Initial Statement of Beneficial 0 --
2026-06-21 Lauren Tyler Independent Director Open Market Acquisition +550 $270.23
2026-06-17 Mark M. Durcan Lead Independent Director Open Market Acquisition +4,000 $274.19
2026-05-27 Mark M. Durcan Lead Independent Director Open Market Acquisition +4,000 $266.26

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

Cencora医药 讨论区 0 条评论

发表评论